STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.

Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.

Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.

Rhea-AI Summary
Amgen announces positive results for tarlatamab in patients with advanced small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Amgen to host webcasted call for investment community following presentation of new data from oncology portfolio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
Rhea-AI Summary
Amgen presents new data at ESMO Congress 2023, highlighting potential of various therapies in tough-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
Rhea-AI Summary
Amgen completes acquisition of Horizon Therapeutics for $27.8 billion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary
deCODE Genetics scientists release findings from plasma proteomics study, demonstrating how it can contribute to understanding diseases. Associations found between diseases and specific proteins. Leveraging genetic factors can uncover molecular mechanisms of disease development. Data from 50,000 individuals analyzed using two platforms. Discrepancies between platforms affect biomarker discovery. Validation of individual assays necessary. deCODE is a global leader in genome analysis. Wholly-owned subsidiary of Amgen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
Rhea-AI Summary
Amgen launches Amgen Partners of Choice network to advance collaboration in oncology research and development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary
Scientists at deCODE genetics, a subsidiary of Amgen, publish a study on the complex effects of sequence variants on lipid levels and coronary artery disease. The study shows that carriers of a particular sequence variant are protected against the negative effects of alcohol consumption on coronary artery disease. Carriers of another sequence variant are more susceptible to increases in bad cholesterol upon consumption of oily fish. The study also demonstrates that homozygotes of the APOE2 allele have high levels of bad cholesterol but fewer particles carrying the cholesterol, conferring similar risk of developing coronary artery disease as non-carriers. Blood group secretor status influences cholesterol levels and cardiovascular disease risk among individuals not in the A1 blood group. These findings highlight the complex interaction between the genome and the environment in affecting health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary
Amgen to present at Bank of America Merrill Lynch Global Healthcare Conference on Sept. 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
-
Rhea-AI Summary
Amgen announces positive data from Phase 1b study of LUMAKRAS in first-line treatment of KRAS G12C-mutated NSCLC, with a confirmed objective response rate of 65% and disease control rate of 100%. Phase 3 study initiated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Amgen to present at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences
Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

150.87B
536.44M
0.22%
82.06%
3.01%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS